Relevant bibliographies by topics / SARS-CoV-2 Vaccine

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'SARS-CoV-2 Vaccine'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'SARS-CoV-2 Vaccine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "SARS-CoV-2 Vaccine"

1

Sheibak, V. M., and M. V. Haretskaya. "DEVELOPMENT OF VACCINES FOR SARS-COV-2." Journal of the Grodno State Medical University 20, no. 1 (2022): 5–12. http://dx.doi.org/10.25298/2221-8785-2022-20-1-5-12.

Full text
Abstract:
Background. Currently, an active search for effective vaccines against the SARS-CoV-2 coronavirus continues. Purpose. To analyze the literature and assess the status of active vaccine development against SARS-CoV-2. Material and methods. We analyzed Russian and English language literature sources on the problem of finding an effective vaccine against SARS-CoV-2. Results. Structural proteins of the coronavirus have been analyzed as basic compounds for the development of vaccines. It was found that protein S is an ideal structure for creating vaccines that effectively induce the synthesis of neu
APA, Harvard, Vancouver, ISO, and other styles
2

Bretón I, Andrea, and Alejandro Afani S. "Vacunas SARS-CoV-2." Revista Hospital Clínico Universidad de Chile 32, no. 2 (2021): 168–76. http://dx.doi.org/10.5354/2735-7996.2021.69660.

Full text
Abstract:
Vaccines are biological products that stimulate the immune system to generate specific responses and immune memory. Faced with the magnitude of the problem caused by the Covid-19 pandemic, there is an urgent need to find an effective and safe preventive intervention. The race to find the ideal vaccine against this new coronavirus has required optimizing research times on this topic. Currently, more than 200 SARS-CoV-2 vaccine candidates are in development, 177 in preclinical evaluation, 63 in clinical evaluation and 16 of them in phase 3 of clinical trials. In our country, 3 SARS-CoV-2 vaccine
APA, Harvard, Vancouver, ISO, and other styles
3

Bellamkonda, Navya, Upendra Pradeep Lambe, Sonali Sawant, Shyam Sundar Nandi, Chiranjib Chakraborty, and Deepak Shukla. "Immune Response to SARS-CoV-2 Vaccines." Biomedicines 10, no. 7 (2022): 1464. http://dx.doi.org/10.3390/biomedicines10071464.

Full text
Abstract:
COVID-19 vaccines have been developed to confer immunity against the SARS-CoV-2 infection. Prior to the pandemic of COVID-19 which started in March 2020, there was a well-established understanding about the structure and pathogenesis of previously known Coronaviruses from the SARS and MERS outbreaks. In addition to this, vaccines for various Coronaviruses were available for veterinary use. This knowledge supported the creation of various vaccine platforms for SARS-CoV-2. Before COVID-19 there are no reports of a vaccine being developed in under a year and no vaccine for preventing coronavirus
APA, Harvard, Vancouver, ISO, and other styles
4

Ebrahim, Fawzi, Salah Tabal, Yosra Lamami, et al. "Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 or Post-Vaccination in Libyan Population: Comparison of Four Vaccines." Vaccines 10, no. 12 (2022): 2002. http://dx.doi.org/10.3390/vaccines10122002.

Full text
Abstract:
Measurement of strength and durability of SARS-COV-2 antibody response is important to understand the waning dynamics of immune response to both vaccines and infection. The study aimed to evaluate the level of IgG antibodies against SARS-CoV-2 and their persistence in recovered, naïve, and vaccinated individuals. We investigated anti-spike RBD IgG antibody responses in 10,000 individuals, both following infection with SARS-CoV-2 and immunization with SARS-COV-2 AstraZeneca, Sputnik V, Sinopharm, and Sinovac. The mean levels of anti-spike IgG antibodies were higher in vaccinated participants wi
APA, Harvard, Vancouver, ISO, and other styles
5

ISI-SENAI-CIMATEC Group and Development and Innovation Laboratory of Butantan Institute. "Vaccines’ Candidates Against SARS-CoV-2." JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH 3, no. 2 (2020): 249–66. http://dx.doi.org/10.34178/jbth.v3i2.126.

Full text
Abstract:
Scientists, health organizations, and pharmaceutical companies are making a large global effort to develop vaccines against SARS-CoV-2, the virus of COVID-19 since the outbreak began. Until now, we have more than 150 candidates. However, 19 vaccine candidates have entered clinical trials in phase 2 and 3 trials (31 July 2020). In this article we aimed to present the platforms for COVID-19 vaccine, the types of vaccines (live, attenuated, inactivated, DNA/RNA, proteins subunits, viral vector), the antigen selection, adjuvants, and we focused on the phase 2/3 trial vaccines at this point (Sinoph
APA, Harvard, Vancouver, ISO, and other styles
6

Geng, Qibin, Wanbo Tai, Victoria K. Baxter, et al. "Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection." PLOS Pathogens 17, no. 9 (2021): e1009897. http://dx.doi.org/10.1371/journal.ppat.1009897.

Full text
Abstract:
The key to battling the COVID-19 pandemic and its potential aftermath is to develop a variety of vaccines that are efficacious and safe, elicit lasting immunity, and cover a range of SARS-CoV-2 variants. Recombinant viral receptor-binding domains (RBDs) are safe vaccine candidates but often have limited efficacy due to the lack of virus-like immunogen display pattern. Here we have developed a novel virus-like nanoparticle (VLP) vaccine that displays 120 copies of SARS-CoV-2 RBD on its surface. This VLP-RBD vaccine mimics virus-based vaccines in immunogen display, which boosts its efficacy, whi
APA, Harvard, Vancouver, ISO, and other styles
7

Walker, Karrie. "SARS-CoV-2 Vaccine." Global Reproductive Health 5, no. 3 (2020): e42-e42. http://dx.doi.org/10.1097/grh.0000000000000042.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhang, Qiong, Shashi Tiwari, Jing Wen, et al. "Induction of neutralizing antibodies against SARS-CoV-2 variants by a multivalent mRNA-lipid nanoparticle vaccine encoding SARS-CoV-2/SARS-CoV Spike protein receptor-binding domains in mice." PLOS ONE 19, no. 4 (2024): e0300524. http://dx.doi.org/10.1371/journal.pone.0300524.

Full text
Abstract:
To address the need for multivalent vaccines against Coronaviridae that can be rapidly developed and manufactured, we compared antibody responses against SARS-CoV, SARS-CoV-2, and several variants of concern in mice immunized with mRNA-lipid nanoparticle vaccines encoding homodimers or heterodimers of SARS-CoV/SARS-CoV-2 receptor-binding domains. All vaccine constructs induced robust anti-RBD antibody responses, and the heterodimeric vaccine elicited an IgG response capable of cross-neutralizing SARS-CoV, SARS-CoV-2 Wuhan-Hu-1, B.1.351 (beta), and B.1.617.2 (delta) variants.
APA, Harvard, Vancouver, ISO, and other styles
9

Hou, Xu-Chen, Hui-Fang Xu, Yang Liu, et al. "A Vaccine with Multiple Receptor-Binding Domain Subunit Mutations Induces Broad-Spectrum Immune Response against SARS-CoV-2 Variants of Concern." Vaccines 10, no. 10 (2022): 1653. http://dx.doi.org/10.3390/vaccines10101653.

Full text
Abstract:
With the emergence of more variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the immune evasion of these variants from existing vaccines, the development of broad-spectrum vaccines is urgently needed. In this study, we designed a novel SARS-CoV-2 receptor-binding domain (RBD) subunit (RBD5m) by integrating five important mutations from SARS-CoV-2 variants of concern (VOCs). The neutralization activities of antibodies induced by the RBD5m candidate vaccine are more balanced and effective for neutralizing different SARS-CoV-2 VOCs in comparison with those induced by th
APA, Harvard, Vancouver, ISO, and other styles
10

Thomas, Whitney, Adam Albano, Dean Kirkel, Nason Rouhizad, and Folasade Arinze. "Immune Thrombocytopenic Purpura following Administration of mRNA-Based SARS-CoV-2 and MMR Vaccinations: A Cautionary Tale." Case Reports in Infectious Diseases 2021 (October 9, 2021): 1–4. http://dx.doi.org/10.1155/2021/2704249.

Full text
Abstract:
We report a case of immune thrombocytopenic purpura (ITP) in an otherwise healthy 31-year-old man following coadministration of the live measles, mumps, and rubella (MMR) vaccine with the Pfizer-BioNTech mRNA SARS-CoV-2 vaccine. The patient was hospitalized briefly and treated for ITP with glucocorticoids, IVIG, and platelet transfusion. Although our patient’s clinical presentation and subsequent course are similar to those of other cases of ITP in association with SARS-CoV-2 vaccination, to our knowledge, this is the first reported case of ITP following MMR and mRNA SARS-CoV-2 vaccine coadmin
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "SARS-CoV-2 Vaccine"

1

Chenane, Houssem Eddine. "Étude de marqueurs sérologiques et génomiques des virus respiratoires SARS-CoV-2 et VRS." Electronic Thesis or Diss., Université Paris Cité, 2025. https://wo.app.u-paris.fr/cgi-bin/WebObjects/TheseWeb.woa/wa/show?t=7854&f=76741.

Full text
Abstract:
Depuis son émergence en 2019, le SARS-CoV-2 a engendré une pandémie mondiale sans précédent, bouleversant les systèmes de santé et provoquant une crise sanitaire majeure. Le diagnostic de la COVID-19 repose principalement sur la détection de l'ARN viral par RT-PCR nasopharyngée, mais la quantification de l'antigène N dans le sérum (antigénémie N) pourrait offrir une alternative précieuse en tant que marqueur pronostique de la sévérité de la maladie. Par ailleurs, l'apparition continue de nouveaux variants, porteurs de mutations sur la protéine de spicule S, a amplifié les défis posés par la pa
APA, Harvard, Vancouver, ISO, and other styles
2

ALTAMIRA, Asociación Peruana de Bibliotecas Académicas. "Boletín diario de información científica N° 15." Asociación Peruana de Bibliotecas Académicas ALTAMIRA, 2020. http://hdl.handle.net/10757/651864.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

ALTAMIRA, Asociación Peruana de Bibliotecas Académicas. "Boletín diario de información científica N° 26." Asociación Peruana de Bibliotecas Académicas ALTAMIRA, 2020. http://hdl.handle.net/10757/651935.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

ALTAMIRA, Asociación Peruana de Bibliotecas Académicas. "Boletín diario de información científica N° 14." Asociación Peruana de Bibliotecas Académicas ALTAMIRA, 2020. http://hdl.handle.net/10757/651857.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Svensson, Adrian. "En jämförelse av olika covid-19 vaccin." Thesis, Malmö universitet, Fakulteten för hälsa och samhälle (HS), 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:mau:diva-44521.

Full text
Abstract:
Bakgrund: I slutet av 2019 upptäcktes flertalet fall av pneumoni av okänd etiologi i Wuhan, Kina. Efter isolering och sekvensering framkom det att det rörde sig om ett coronavirus, benämnt SARS-CoV-2. Sociala restriktioner och munskydd har inte lyckats stoppa denna pandemi, och hoppet ligger nu på de olika vaccinkandidater som började utvecklas under 2020. Syfte: Syftet var att jämföra olika vaccins effektivitet och förekomst av olika biverkningar. Metod: En systemisk litteraturstudie utfördes, där en sökning i Pubmed utfördes och fyra artiklar valdes ut till arbetet för att jämföra vaccineffe
APA, Harvard, Vancouver, ISO, and other styles
6

Wrywood, Sean. "Vaccin mot SARS-CoV-2 – en utvärdering av effektivitet och säkerhet av ledande vaccin : En Litteraturstudie." Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-104678.

Full text
Abstract:
Introduktion: Coronavirus är RNA-virus med ett lipidhölje som är täckt utav karaktäristiska spikprotein. De mest kända coronavirusvarianterna är SARS-CoV-1 som var aktiv mellan 2002-2004, MERS-CoV som har varit aktiv sedan 2012 och SARS-CoV-2 som har varit aktiv sedan 2019–tillsvidare. SARS-CoV-2 infektionen betecknades januari 30 2020 som en pandemi. Flera läkemedelsföretag har forcerat ??? till att framställa vaccin riktad mot SARS-CoV-2, “The United States Food and Drug Administration” (FDA) och “European Medicines Agency” (EMA) har nödgats att ge ut “Emergency Use Authorization (EUA) i hop
APA, Harvard, Vancouver, ISO, and other styles
7

Filippini, Federica. "VALUTAZIONE DELLA RISPOSTA UMORALE E CELLULO-MEDIATA CONTRO SARS-COV-2 EVOCATA DAL VACCINO PFIZER mRNA BNT162b2 IN PAZIENTI IMMUNOSOPPRESSI." Doctoral thesis, Università degli studi di Brescia, 2023. https://hdl.handle.net/11379/570888.

Full text
Abstract:
In questo lavoro di tesi è stata valutata la risposta immunitaria umorale e cellulo-mediata, in seguito alla somministrazione del vaccino a mRNA anti-COVID-19 (Pfizer mRNA BNT162b2), in pazienti trattati con farmaci immunosoppressi e con immunodeficienza comune variabile (CVID). Dall’Unità di Reumatologia e Immunologia Clinica, dell’A.O. Spedali Civili di Brescia sono stati reclutati 38 pazienti, di cui 34 affetti da malattie reumatiche croniche (RDs), 4 da CVID e 11 persone sane (HC), utilizzate come controlli. Tutti i pazienti con RDs erano sottoposti ad una terapia a base di corticosteroid
APA, Harvard, Vancouver, ISO, and other styles
8

Ganser, Iris. "Utilisation des modèles mathématiques face à la COVID-19 : analyse des effets des interventions en santé publique et de la dynamique immunitaire." Electronic Thesis or Diss., Bordeaux, 2024. http://www.theses.fr/2024BORD0351.

Full text
Abstract:
La pandémie de COVID-19, causée par le SRAS-CoV-2, a entrainé une morbidité et une mortalité importantes, mettant à rude épreuve les systèmes de santé mondiaux. Les vaccinations et les interventions non pharmaceutiques (INP) sont essentielles pour contrôler la propagation du virus. Avant les vaccins, les gouvernements s’appuyaient sur des INP dont l’impact épidémiologique et sociétal restait incertain, notamment sur plusieurs vagues pandémiques. Le déploiement des vaccins a augmenté l’immunité collective, mais l’émergence de variants préoccupants (VoCs) échappant à l’immunité et l’affaiblissem
APA, Harvard, Vancouver, ISO, and other styles
9

Murer, Bianca. "Emergenza e pandemia: Traduzioni dal sito web del Robert Koch Institut." Bachelor's thesis, Alma Mater Studiorum - Università di Bologna, 2021.

Find full text
Abstract:
Ci troviamo in un singolare momento storico dovuto alla pandemia. In tutto il mondo si sono prodotti enormi cambiamenti della vita quotidiana, sono stati, e continuano ad essere, presi provvedimenti restrittivi al riguardo. Quest’emergenza sanitaria internazionale è qualcosa di nuovo, e nonostante gli studi sul SARS-CoV-2 siano moltissimi, le domande rimangono tante e altrettanti sono i dettagli che ancora non si sanno. In Germania il Robert Koch Institut è l’ente di riferimento per la situazione sanitaria, e attraverso il Covid è diventato ancora più importante. La voglia di rendere accessibi
APA, Harvard, Vancouver, ISO, and other styles
10

Malladi, Sameer Kumar. "HIV-1 and SARS-CoV-2 immunogen design." Thesis, 2020. https://etd.iisc.ac.in/handle/2005/5595.

Full text
Abstract:
Human Immunodeficiency Virus (HIV-1) is the aetiologic agent of AIDS. Presently there are ~38 million HIV-1 infected individuals worldwide and ~1 million deaths in 2019. Since its discovery, the quest for vaccine candidate for HIV-1 is alive, yet no effective vaccine exists till date. HIV-1 viral displayed Envelope (Env) protein is the primary viral target of the humoral immune system and is thus an obvious vaccine candidate. The historic RV144 HIV-1 clinical trial resulted in a modest efficacy of the gp120 clade B/E vaccine candidate and renewed hope in finding a HIV-1 vaccine. However, monom
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "SARS-CoV-2 Vaccine"

1

Mueller, Siguna. Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-18903-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Saha, Indrajit, Dariusz Plewczynski, and Nimisha Ghosh, eds. SARS-CoV-2: From Genetic Variability to Vaccine Design. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-83250-176-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

SARS-CoV-2: Testing and Treating Covid-19. Should You Get the Vaccine? Part 2 Of 2. Independently Published, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

SARS-CoV-2 Variants and Global Population Vulnerability: Diagnostic Strategies, Vaccine Development, and Therapeutic Management. Apple Academic Press, Incorporated, 2024.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

SARS-CoV-2 Variants and Global Population Vulnerability: Diagnostic Strategies, Vaccine Development, and Therapeutic Management. Apple Academic Press, Incorporated, 2024.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Crawford, Dorothy H. Viruses: A Very Short Introduction. 3rd ed. Oxford University PressOxford, 2022. http://dx.doi.org/10.1093/actrade/9780192865069.001.0001.

Full text
Abstract:
Abstract Viruses: A Very Short Introduction examines the recent rise in emerging virus infections, especially coronaviruses. It explores why SARS-CoV-2 was able to spread rapidly and cause a pandemic, as opposed to more localized epidemics. It also highlights the recent revolution in vaccine technology and other preventive measures for the management of future dangerous viruses that will undoubtedly emerge. This VSI provides a rounded and concise account of the nature of viruses, how they attack their hosts, and the efforts to control them. Viruses are everywhere and, as the COVID-19 pandemic
APA, Harvard, Vancouver, ISO, and other styles
7

Medeiros, Mauricio, Beatriz Fialho, Priscila Soares, and Daniel Lacerda, eds. A primeira vacina 100% brasileira contra a Covid-19: a conquista de Bio-Manguinhos/Fiocruz. Fundação Oswaldo Cruz / Bio-Manguinhos, 2022. http://dx.doi.org/10.35259/vacinacovid.2022_52830.

Full text
Abstract:
The Covid-19 pandemic is a unique event in the modern history of humanity, which has generated great challenges and, at the same time, valuable opportunities for public health. A number of examples of them are found in the more than three hundred pages of this book. In each chapter it is possible to understand how a vaccine for Covid-19 was developed in record time - due to the urgency of an antidote that would allow us to deal with this terrible disease - through the acceleration, compliance and improvement of all labor criteria, production, evaluation, timely release, and security. This enti
APA, Harvard, Vancouver, ISO, and other styles
8

MARROQUÍN-DE JESÚS, Ángel, Juan Manuel OLIVARES-RAMÍREZ, Marisela CRUZ-RAMÍREZ, and Luis Eduardo CRUZ-CARPIO. CIERMMI Women in Science Engineering and Technology TXV. ECORFAN, 2021. http://dx.doi.org/10.35429/h.2021.6.1.180.

Full text
Abstract:
In recent years, society has achieved a better quality of life; this has been possible thanks to scientific and technological advances. Among the advances that have allowed us to move forward is, without a doubt, the development of the vaccine against the SARS-CoV-2 virus. The method used for the synthesis of this vaccine was developed by Ugur Sahin and Öezlem Türeci, founders of BioNTech. Yes, behind the scientific development of greatest impact and relevance in recent years are a man and a woman. This scientific development was possible thanks to both of them, and here it is important to hig
APA, Harvard, Vancouver, ISO, and other styles
9

Singh, Pankaj Kumar, Dharmendra Kumar Khatri, Shashi Bala Singh, and Anitha Sriram, eds. An Update on SARS-CoV-2: Damage-response Framework, Potential Therapeutic Avenues and the Impact of Nanotechnology on COVID-19 Therapy Volume 1. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/97898150398631220101.

Full text
Abstract:
This update on SARS-CoV-2 focuses on basic knowledge about the virus and COVID-19 treatment. Chapters present basic information about the disease and its treatment. The virology, epidemiology, etiology, and damage response framework of SARS-CoV-2 are also discussed in detail. The book also covers recent topics of interest to pharmacology scholars such as the immunopathogenesis of SARS-CoV2, nanotechnology, repurposed drug treatments, COVID-19 vaccines, and phytomedicine for COVID-19 therapeutics. Readers in pharmacology, virology and medicine will find the book a simple, yet informative update
APA, Harvard, Vancouver, ISO, and other styles
10

Mueller, Siguna. Challenges and Opportunities of MRNA Vaccines Against SARS-CoV-2: A Multidisciplinary Perspective. Springer International Publishing AG, 2022.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "SARS-CoV-2 Vaccine"

1

Jain, Ananya, and Shilpa Sharma. "Nanotechnology in COVID-19 Vaccines." In Proceedings of the Conference BioSangam 2022: Emerging Trends in Biotechnology (BIOSANGAM 2022). Atlantis Press International BV, 2022. http://dx.doi.org/10.2991/978-94-6463-020-6_3.

Full text
Abstract:
AbstractNanotechnology has been proposed in vaccine development as carriers and adjuvants time and again but received limited recognition before the development of vaccines for the COVID-19 pandemic. Nanotechnology has played a pivotal role in the triumph of the vaccines for the current pandemic caused by the SARS-CoV-2 virus. The first vaccine got approved within a year of the earliest reported case of the novel coronavirus. Presently, more than 35 vaccines are approved in at least one country, 10 out of which are sanctioned for emergency use by the WHO. The key categories include peptide vac
APA, Harvard, Vancouver, ISO, and other styles
2

Magnus, Clara Luzia, and Barbara Schmidt. "SARS-CoV-2 Vaccine Against Virus: Mission Accomplished!?" In Frontiers of COVID-19. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08045-6_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mueller, Siguna. "Relevance for mRNA Vaccine Safety." In Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-18903-6_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Paschall, Amy V., and Fikri Y. Avci. "Chapter 5. Pathogenesis and Immunity of SARS-CoV-2 and Vaccination Programs Against COVID-19." In Vaccine Development. Royal Society of Chemistry, 2022. http://dx.doi.org/10.1039/9781839162572-00112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kumar, Anup, Dixa A. Vaghela, Pankti C. Balar, et al. "Nasal Vaccine for the Control of Emerging Variants of SARS-CoV-2." In SARS-CoV-2 Variants and Global Population Vulnerability. Apple Academic Press, 2024. http://dx.doi.org/10.1201/9781003467939-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Aljabali, Alaa A. A., Mohammad A. Obeid, and Murtaza M. Tambuwala. "Fast Track Vaccine Development for COVID-19 and Impact of Emerging Variants." In SARS-CoV-2 Variants and Global Population Vulnerability. Apple Academic Press, 2024. http://dx.doi.org/10.1201/9781003467939-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mueller, Siguna. "The Challenge of Evaluating Vaccine Safety and Effectiveness." In Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-18903-6_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bok, Karin. "12.1 In Focus: Novel Manufacturing Platforms for Pandemic Preparedness and Emergency Response." In Principles and Practice of Emergency Research Response. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-48408-7_15.

Full text
Abstract:
AbstractThis feature focuses on several relatively novel (mRNA, DNA, and vector-based) manufacturing platforms for vaccine design that can facilitate rapid response to infectious disease emergencies caused by emerging and re-emerging pathogens, such as Ebola virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Both gene- and vector-based platforms can deliver well-designed vaccine antigens inducing humoral and cellular immunity while avoiding most vaccine-associated safety concerns and limitations (integration into the host cell genome or anti-vector immunity). The manufactu
APA, Harvard, Vancouver, ISO, and other styles
9

Mueller, Siguna. "mRNA Vaccine Safety and Efficacy—Official Criteria When AEs Are Caused by the Injection." In Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-18903-6_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pathak, Drishya. "COVID-19 Vaccination: A Necessitated Drive Becoming an Unsolved Puzzle." In Global Perspectives of COVID-19 Pandemic on Health, Education, and Role of Media. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-99-1106-6_9.

Full text
Abstract:
AbstractThe scientific community has achieved a remarkable feat by developing COVID-19 vaccines in a record duration of 12 months. The fastest vaccine developed and deployed previously was within a time-frame of four years, to prevent mumps in the 1960s. The speedy approach to prevent SARS-CoV-2 has changed the future of vaccine science with several vaccines showing excellent results in large trials. The COVID-19 vaccination strategy is of crucial importance for controlling the pandemic. As the vaccination mandate was faster than information dissemination, and even faster than the clinical tri
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "SARS-CoV-2 Vaccine"

1

Shi, Xinyu, Yixin Tao, and Shih-Chi Lin. "Deep Neural Network-Based Prediction of B-Cell Epitopes for SARS-CoV and SARS-CoV-2: Enhancing Vaccine Design through Machine Learning." In 2024 4th International Signal Processing, Communications and Engineering Management Conference (ISPCEM). IEEE, 2024. https://doi.org/10.1109/ispcem64498.2024.00050.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"Emergence of SARS-CoV-2 Variant of Concern Omicron: Biological Features and Genomic Concern." In International Conference on Public Health and Humanitarian Action. International Federation of Medical Students' Associations - Jordan, 2022. http://dx.doi.org/10.56950/itrx2370.

Full text
Abstract:
Abstract Corona virus infection is a worldwide health threat that has infected a substantial portion of the world's population and is caused by SARS-CoV-2. It is the natural tendency of a virus to change the genetic makeup through the point mutation, and such viruses are called the variant of the original virus. SARS-CoV-2 virus also undergoes such mutation (may be one or more and distinct from other) over time, and many genetically diverse variant has risen. Such variants might be of variants of concern (VOC) and variant of interest (VOI) based on the differences in virulence, transmissibilit
APA, Harvard, Vancouver, ISO, and other styles
3

Emi Aikawa, Nádia, Léonard de Vinci Kanda Kupa, Sandra Gofinet Pasoto, et al. "DYNAMICS OF INACTIVATED SARS-COV-2 VACCINE ANTIBODY RESPONSE IN SARS-COV-2-SEROPOSITIVE AUTOIMMUNE RHEUMATIC DISEASE PATIENTS." In SBR 2021 Congresso Brasileiro de Reumatologia. Sociedade Brasileira de Reumatologia, 2021. http://dx.doi.org/10.47660/cbr.2021.1905.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lupu, Vasile Valeriu, Ingrith Miron, Anamaria Ciubara, et al. "SARS COV 2 PANDEMIC - BETWEEN CAUTION AND PRUDENCE." In The European Conference of Psychiatry and Mental Health "Galatia". Archiv Euromedica, 2023. http://dx.doi.org/10.35630/2022/12/psy.ro.3.

Full text
Abstract:
There is no doubt that a natural phenomenon of the magnitude of a pandemic requires a series of tough precautionary measures in order to limit the spread of the disease, to combat the manifestations of the disease by appropriate therapeutic means and to increase the resistance of the population through prophylactic immunisation, namely vaccination. At the same time, caution points out that not all precautionary measures achieve their aim, for at least two reasons: first, it is an extremely versatile micro-organism (like any virus) which can change its genetic configuration through mutations, t
APA, Harvard, Vancouver, ISO, and other styles
5

Luche, DD. "SARS-COV-2 NT-CHIP, A NOVEL FUNCTIONAL MULTIPLEX IMMUNOASSAY FOR SARS-COV-2 EVALUATION OF HUMORAL RESPONSE AND DETECTION OF NEUTRALIZING ANTIBODIES." In Resumos do 54º Congresso Brasileiro de Patologia Clínica/Medicina Laboratorial. Zeppelini Editorial e Comunicação, 2022. http://dx.doi.org/10.5327/1516-3180.140s1.7075.

Full text
Abstract:
Objective: Here we present the initial development and characterization of the Sars-CoV-2 NT-Chip. This test allows combining general detection of binding antibodies against RBDs (humoral signature) and, in the same assay, to detect and quantify the subset of these antibodies that promote functional neutralization against Sars-CoV-2 infection. Moreover, high detection of antibodies against N suggests previous infection for Omicron-positive samples. Method: The Sars-CoV-2 VOC Virachip IgG test was first developed to promote a multiplex detection of binding antibodies against the Sars-CoV-2 prot
APA, Harvard, Vancouver, ISO, and other styles
6

Dubrovskaya, E. V., D. I. Ivkina, and A. R. Imatdinov. "RECOMBINANT INFLUENZA A VIRUS REASSORTANT VACCINE STRAIN EXPRESSING MODIFIED RBD FRAGMENT OF SARS-COV-2 CORONAVIRUS SPIKE GLYCOPROTEIN." In OpenBio-2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-244.

Full text
Abstract:
Influenza A virus and SARS-CoV-2 virus have a high pandemic potential. Vaccination is an effective method of prevention, but existing vaccines cannot be quickly updated to match circulating virus variants. This paper describes a recombinant reassortant strain of influenza A virus expressing SARS-CoV-2 trimerized RBD, which can be used as a component of candidate multivalent vaccines.
APA, Harvard, Vancouver, ISO, and other styles
7

Legostaev, S. S., E. V. Protopopova, R. Yu Lutkovsky, and V. A. Svyatchenko. "STUDY OF THE EFFECTS OF SARS-COV-2 CO-INFECTION WITH A NON-PATHOGENIC VARIANT OF THE COXSACKIE A7 VIRUS (LEV-8 STRAIN) AND ENTEROVIRUS 71." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-256.

Full text
Abstract:
The paper presents the results of the study of the effects of co-infection of SARS-CoV-2 with non-pathogenic for humans strain LEV-8 (live enterovirus vaccine) of Coxsackie virus A7 and enterovirus 71 (EV71) on the model of cell cultures and laboratory animals. In vitro experiments showed that during infection enteroviruses and SARS-CoV-2 have a competitive inhibitory effect on each other, with a more pronounced degree of suppression of SARS-CoV-2. Modeling of SARS-CoV-2 co-infection with enteroviruses in laboratory animals showed that preliminary infection with enteroviruses leads to a pronou
APA, Harvard, Vancouver, ISO, and other styles
8

Kisakova, L. A., D. N. Kisakov, V. A. Yakovlev та ін. "СOMPARATIVE ANALYSIS OF IMMUNOGENICITY OF MRNA CONSTRUCTS ENCODING RBD PROTEIN S OF SARS-COV-2 VIRUS AND HEMAGGLUTININ OF INFLUENZA TYPE A (H1N1) VIRUS DELIVERED BY MAGNETIC AND LIPID NANOPARTICLES". У XI МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ МОЛОДЫХ УЧЕНЫХ: БИОИНФОРМАТИКОВ, БИОТЕХНОЛОГОВ, БИОФИЗИКОВ, ВИРУСОЛОГОВ, МОЛЕКУЛЯРНЫХ БИОЛОГОВ И СПЕЦИАЛИСТОВ ФУНДАМЕНТАЛЬНОЙ МЕДИЦИНЫ. IPC NSU, 2024. https://doi.org/10.25205/978-5-4437-1691-6-328.

Full text
Abstract:
The use of lipid nanoparticles for the delivery of mRNA vaccines encoding the SARS-COV-2 virus RBD protein S and the influenza A (H1N1) virus hemagglutinin produced a significant increase in humoral and T-cell responses. However, the application of magnetic nanoparticles did not show activation of both parts of the immune response and needs further optimization of the mRNA vaccine delivery method.
APA, Harvard, Vancouver, ISO, and other styles
9

Kudrov, G. A., S. S. Zainutdinov, I. S. Shulgina, et al. "PROTECTIVE PROPERTIES OF MUCOSAL VACCINE AGAINST COVID-19 BASED ON RECOMBINANT VARIANT OF SENDAI VIRUS STRAIN MOSCOW." In XI МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ МОЛОДЫХ УЧЕНЫХ: БИОИНФОРМАТИКОВ, БИОТЕХНОЛОГОВ, БИОФИЗИКОВ, ВИРУСОЛОГОВ, МОЛЕКУЛЯРНЫХ БИОЛОГОВ И СПЕЦИАЛИСТОВ ФУНДАМЕНТАЛЬНОЙ МЕДИЦИНЫ. IPC NSU, 2024. https://doi.org/10.25205/978-5-4437-1691-6-193.

Full text
Abstract:
A vaccine construct Sen-Sdelta(M), which expresses the full-length spike (S) protein of SARS-CoV-2 delta variant, was developed based on Sendai virus strain Moscow. Using the Syrian hamster model, it was shown that a single intranasal vaccination with Sen-Sdelta(M) induces high titers of virus-neutralizing antibodies specific to SARS-CoV-2 and protects animals from the development of coronavirus infection.
APA, Harvard, Vancouver, ISO, and other styles
10

Yakovlev, V. A., M. B. Borgoyakova, E. V. Tigeeva, D. N. Kisakov, L. A. Kisakova, and L. I. Karpenko. "BOOSTER IMMUNIZATION OF MICE WITH A CANDIDATE POLYEPITOPE DNA VACCINE USING JET INJECTION LEADS TO A SIGNIFICANT INCREASE IN THE T-CELL IMMUNE RESPONSE." In XI МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ МОЛОДЫХ УЧЕНЫХ: БИОИНФОРМАТИКОВ, БИОТЕХНОЛОГОВ, БИОФИЗИКОВ, ВИРУСОЛОГОВ, МОЛЕКУЛЯРНЫХ БИОЛОГОВ И СПЕЦИАЛИСТОВ ФУНДАМЕНТАЛЬНОЙ МЕДИЦИНЫ. IPC NSU, 2024. https://doi.org/10.25205/978-5-4437-1691-6-367.

Full text
Abstract:
The T-cell immune response is an important part of immunity against SARS-CoV-2. In this work, it was shown that the developed candidate DNA vaccine pBSI-COV-Ub has the ability to induce T-cell immunity in Balb/c mice. The immune response was most effectively stimulated by double intramuscular administration of the vaccine, followed by booster immunization using jet injection.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "SARS-CoV-2 Vaccine"

1

Bymark, Jeff. SARS-CoV-2 Vaccine Development. Iowa State University, 2021. http://dx.doi.org/10.31274/cc-20240624-1255.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Harris, Jeffrey. The Repeated Setbacks of HIV Vaccine Development Laid the Groundwork for SARS-CoV-2 Vaccines. National Bureau of Economic Research, 2021. http://dx.doi.org/10.3386/w28587.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Heilskov, Madison. A review on the development of multi-epitope vaccine candidates for SARS-CoV-2. Iowa State University, 2020. http://dx.doi.org/10.31274/cc-20240624-78.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Vagnoni, Cristiana. COVID-19 vaccines: Immunisation and prioritisation of eligible groups. Parliamentary Office of Science and Technology, 2020. http://dx.doi.org/10.58248/rr42.

Full text
Abstract:
The UK Government secured early access to 340 million doses of six different COVID-19 vaccine candidates. It is still unknown whether any of them will be able to protect from SARS-CoV-2. In case of a successful vaccine candidate, supply may be initially constrained and therefore priority groups need to be defined.
APA, Harvard, Vancouver, ISO, and other styles
5

Vagnoni, Cristiana. COVID-19 vaccines: July update on research. Parliamentary Office of Science and Technology, 2020. http://dx.doi.org/10.58248/rr35.

Full text
Abstract:
There are almost 150 coronavirus vaccine candidates under development. Only 19 of these are now being tested in humans. Many types of vaccines are rapidly progressing through clinical trials. Only two vaccine candidates have announced large scale Phase 3 trials, involving several thousands of people. Only one candidate has been approved for restricted human use. Measuring a reduction in COVID-19 levels is an obstacle for Phase 3 clinical trials, as they require a high infection rate among the tested population to prove vaccine efficacy. International agreements with countries where SARS-CoV-2
APA, Harvard, Vancouver, ISO, and other styles
6

Mishra, Sharmistha, Nathan M. Stall, Huiting Ma, et al. A Vaccination Strategy for Ontario COVID-19 Hotspots and Essential Workers. Ontario COVID-19 Science Advisory Table, 2021. http://dx.doi.org/10.47326/ocsat.2021.02.26.1.0.

Full text
Abstract:
Ontario’s initial mass COVID-19 vaccination strategy in place until April 8, 2021 was based on per-capita regional allocation of vaccines with subsequent distribution – in order of relative priority – by age, chronic health conditions and high-risk congregate care settings, COVID-19 hotspots, and essential worker status. Early analysis of Ontario’s COVID-19 vaccine rollout reveals inequities in vaccine coverage across the province, with residents of higher risk neighbourhoods being least likely get vaccinated. Accelerating the vaccination of COVID-19 hotspots and essential workers will prevent
APA, Harvard, Vancouver, ISO, and other styles
7

Jenkins, J. Lee, Edbert B. Hsu, Anna Russell, Allen Zhang, Lisa M. Wilson, and Eric B. Bass. Infection Prevention and Control for the Emergency Medical Services and 911 Workforce. Agency for Healthcare Research and Quality (AHRQ), 2022. http://dx.doi.org/10.23970/ahrqepctb42.

Full text
Abstract:
Objectives. To summarize current evidence on exposures to infectious pathogens in the emergency medical services (EMS) and 911 workforce, and on practices for preventing, recognizing, and controlling occupationally acquired infectious diseases and related exposures in that workforce. Review methods. We obtained advice on how to answer four Guiding Questions by recruiting a panel of external experts on EMS clinicians, State-level EMS leadership, and programs relevant to EMS personnel, and by engaging representatives of professional societies in infectious diseases and emergency medicine. We sea
APA, Harvard, Vancouver, ISO, and other styles
8

Bunn, Sarah. COVID-19: Omicron, recent developments, and the likely impact of future variants on the pandemic. Parliamentary Office of Science and Technology, 2022. http://dx.doi.org/10.58248/rr78.

Full text
Abstract:
The Omicron variant of the SARS-CoV-2 virus, which causes COVID-19, has been found across the world since it was first detected in early November 2021. This article describes the characteristics of the variant and its health impacts. It also discusses vaccine effectiveness against the variant and the medium and long-term outlook for the future course of the pandemic.
APA, Harvard, Vancouver, ISO, and other styles
9

Golan, Maureen, Emerson Mahoney, Benjamin Trump, and Igor Linkov. Resilience and Efficiency for the Nanotechnology Supply Chains Underpinning COVID-19 Vaccine Development. Engineer Research and Development Center (U.S.), 2025. https://doi.org/10.21079/11681/49696.

Full text
Abstract:
Nanotechnology facilitated the development and scalable commercialization of many SARS-CoV-2 vaccines. However, the supply chains underpinning vaccine manufacturing have demonstrated brittleness at various stages of development and distribution. Whereas such brittleness leaves the broader pharmacological supply chain vulnerable to significant and unacceptable disruption, strategies for supply chain resilience are being considered across government, academia, and industry. How such resilience is understood and parameterized, however, is contentious. Our review of the nanotechnology supply chain
APA, Harvard, Vancouver, ISO, and other styles
10

Bunn, Sarah. COVID-19 and social distancing: the 2 metre advice. Parliamentary Office of Science and Technology, 2020. http://dx.doi.org/10.58248/rr32.

Full text
Abstract:
An infected person produces respiratory droplets when talking, coughing and sneezing. These are responsible for the transmission of virus between people. Droplets can travel up to 2m, with finer aerosols containing smaller viral particles travelling even further. Numerous complex and interacting factors influence how they move and settle onto surfaces, and how infectious they are. The further away a person is, the fewer droplets they will be exposed to and so their risk of being infected with the virus reduces. The advice on 2 m distancing is a risk assessment based on relative not absolute ri
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'SARS-CoV-2 Vaccine' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography